Advertisement

Topics

Clinical Trials About "signal strength controls thymic differentiation iNKT cell subsets" RSS

05:34 EDT 21st March 2019 | BioPortfolio

We list hundreds of Clinical Trials about "signal strength controls thymic differentiation iNKT cell subsets" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "signal strength controls thymic differentiation iNKT cell subsets" on BioPortfolio

We have published hundreds of signal strength controls thymic differentiation iNKT cell subsets news stories on BioPortfolio along with dozens of signal strength controls thymic differentiation iNKT cell subsets Clinical Trials and PubMed Articles about signal strength controls thymic differentiation iNKT cell subsets for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of signal strength controls thymic differentiation iNKT cell subsets Companies in our database. You can also find out about relevant signal strength controls thymic differentiation iNKT cell subsets Drugs and Medications on this site too.

Showing "signal strength controls thymic differentiation iNKT cell subsets" Clinical Trials 1–25 of 17,000+

Extremely Relevant

Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor

Invariant Natural killer T (iNKT) cells are a unique subset of lymphocytes that express homogeneous TCR recognizing KRN7000 which was up-regulated by many kinds of cancer cells. PD-1+CD8+T cells of patients with advanced tumor are most likely tumor-specified. Our hypothesis is that immunotherapy strategy of infusion of iNKT cells and PD-1+CD8+T cells may decrease the tumor burden and improve overall survival. The purpose of this study is to assess the safety and efficacy of tre...


The Role of TBX3 in Human ES Cell Differentiation

Stem cells can develop into every cell, every tissue and every organ in the human body, e.g., they can make any kind of cells in the human body. Stem cells reproduce themselves many times over and over. Their almost limitless potential has made stem cells a significant focus of medical research. But before scientists can use stem cells for medical purposes, they must first learn how to harness their power. They cannot treat disease until they learn how to manipulate stem ce...

Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC

This study enrolls patients who have relapsed/advanced hepatocellular carcinoma (HCC, BCLC stage C). The HCC tumor relapsed or metastasized through the body after standard treatment or the patients cannot receive standard treatment under current conditions. This research study uses special immune system cells called iNKT cells, a new experimental treatment. The purpose of this study is to find the biggest dose of iNKT cells that is safe and tolerance, to see how long they last...


Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor

Invariant Natural killer T (iNKT) cells are a unique subset of lymphocytes that express homogeneous TCR recognizing KRN7000 which was up-regulated by many kinds of cancer cells.The hypothesis of the investigators is that immunotherapy strategy of infusion of iNKT cells may resist inflection and decrease the tumor burden and improve overall survival. The purpose of this study is to assess the safety and efficacy of treatment of tuberculosis with malignant solid tumor by infusing...

Relevant

Study of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation

The study concerns donors and patients receiving allogeneic stem cell haematopoietic transplantation. The aim of the study is to analyse HSC graft content in immune effector T (naive, memory, activated, exhausted) and immunoregulatory cell subtypes (Tregs, iNKT, MDSC) and correlate the results with post-transplant immune reconstitution of those different cell subtypes and clinical events (graft-versus-host-disease, relapse, infections). An ancillary study will focus on the impa...

Expansion of Invariant NKT Cells for a Cell Immunotherapeutic Approach Allowing the Control of Graft Versus Host-disease and Preserving the Graft Versus Leukemia Effect After Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic hematopoietic stem cell (HSC) transplantation remains the most efficient cellular immunotherapeutic approach for the treatment of myeloid hematological malignancies. However, its use is hampered by the risk of developing acute graft-versus-host disease (aGVHD). Invariant NKT cells (iNKT) represent a good candidate of immuno-regulatory cells that could control GVHD while preserving the anti-leukemic effect (GVL) of HSCT. Our team have shown that higher numbers and exp...

Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma

The intent of the study is to assess the antitumor activity of PHA-848125AC as second-line treatment in patients with recurrent or metastatic, unresectable thymic carcinoma previously treated with chemotherapy.

A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma

This study aims to investigate the clinical activity of sunitinib in patients with advanced thymic carcinoma who have failed chemotherapy.

AZD0530 in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer

RATIONALE: AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well AZD0530 works in treating patients with relapsed or refractory thymoma or thymic cancer.

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

This phase II trial studies how well pembrolizumab and sunitinib malate work in treating participants with thymic cancer that has spread to other places in the body or cannot be removed by surgery and does not respond to treatment. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and sunit...

Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors

the World Health Organization (WHO) has proposed a classification of histopathological thymic tumor and it significance in prognosis. Chest computed tomography (CT) is the most common method to evaluate thymic epithelial tumors before operation. Therefore, the question is to predict the histopathological type of thymic epithelial tumors before surgery based on CT-scan images , to help determine treatment strategy and prognosis. In Vietnam, there are no published literature on t...

Stem Cell Transplantation for Fanconi Anemia

The purpose of this study is to determine whether thymic shielding during total body irradiation can be given and whether it will reduce the risk of infections in Fanconi Anemia patients undergoing alternate donor (not a matched sibling) stem cell transplants.

An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid Arthritis

To study the effects of T cell in peripheral blood of patients with RA undergoing selective B cell depletion have not been studied. We analyze the B and T cell subsets in patients with active RA treated undergoing this form of treatment with rituximab.

A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor

This is a Phase II single center, open-label, single arm study in patients with advanced thymic epithelial tumors after failure of cisplatin-based combination chemotherapy. Patients will be treated with Pembrolizumab 200 mg every 3 weeks.

Biology of Thymic Tumors

This is a retrospective analysis of biological characteristics of thymoma and thymic carcinoma patients.

A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients

To investigate the safety of thymic humoral factor (THF gamma 2), its effect on HIV load based on at least a 75 percent decrease in HIV quantitative PCR RNA copies/ml, and its persistence when administered in combination with an antiretroviral nucleoside derivative (zidovudine; AZT). To assess the effects of THF gamma 2 on T-cells, quality of life, and progression of disease.

Postoperative REcurrence and DynamICs of T Cell Subsets in Crohn's Disease

It is assumed that gut inflammation and lesions characterizing flares of Crohn's disease (CD) result from an aberrant T-cell mediated immune responses characterized by a complex balance between peripheral and lamina propria regulatory and effector T cell subsets. Because most of CD patients who undergo a surgery experienced a postoperative endoscopic recurrence of the disease (70 % at one year) leading to a clinical recurrence (10 % per year), the "model" of postoperative recur...

Effects of Abatacept on Myocarditis in Rheumatoid Arthritis

Animal data showing decreased myocardial inflammation, damage, and mortality, and improved cardiac function with CD40L/B7-1 and CTLA4 blockage, coupled with our preliminary findings of lower myocardial inflammation in RA patients on abatacept vs other DMARDs, suggest that abatacept treatment has potential myocardial benefits. In RA patients, the proportion of peripheral T cell subsets significantly differs from normal controls and include differentiation to memory effector subs...

Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma

There are 2 parts in this study. The goal of Part 1 of this clinical research study is to confirm the highest tolerable dose of pembrolizumab that can be given to patients with unresectable thymoma or thymic cancer. The goal of Part 2 of this clinical research study is to learn if pembrolizumab given at the dose that was found in Part 1 of the study can help to control thymoma or thymic cancer. The safety of the study drug will be studied in both parts. This is an inv...

Strength and Balance in Gender- and Age-Matched Controls

The purpose of this study is to learn more about balance and strength in an elderly population (60 and older). Data will be compared between controls and the age/gender- matched PD participants in study "The Effects of vitamin D on Balance in Parkinson's disease" (OHSU IRB # 6482). Specifically a t-test will be used to compare total work and total power on leg extension and flexion, composite SOT score conditions 1-3 and 4-6, response strength and latency on MCT, and turn dura...

Phase II Study of Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)

The aim of the phase II Nivothym study is to collect data on activity and toxicity of nivolumab therapy in patients with thymic carcinoma or type B3 thymoma that previously received a first platinum-based chemotherapy.

Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for Lymphoma

This is a retrospective, single-center, non-randomized, non-controlled study. This study aims to explore the effect of T-lymphocyte subsets changes in immunologic reconstitution and prognosis in lymphoma patients who were treated by autologous stem cell transplantation.

Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma

To study the efficacy of Alimta as a single agent in thymic cancers

Study of Concurrent Chemoradiotherapy for Locally Advanced (Stage Ⅲ/Ⅳa) Thymoma or Thymic Carcinoma

This study is designed to evaluate the feasibility and safety of concurrent chemoradiotherapy for locally advanced thymoma or thymic carcinoma.

Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study

To determine if pulsed electric field therapy reduces lower leg and foot pain associated with diabetic neuropathy and lessens the need for medication. The MedRelief device sends a sub-threshold electric signal through the skin using electrodes as means of signal delivery. The signal or waveform, frequency and strength were created to match the characteristics of signals the body generates to help natural healing.


More From BioPortfolio on "signal strength controls thymic differentiation iNKT cell subsets"

Advertisement
Quick Search
Advertisement
Advertisement